American Association for Cancer Research

Poster Session D

Poster Session D
Tuesday, February 9
3:30 p.m.-5:00 p.m.

In alphabetical order, not board assignment order

  • A comprehensive screening of shRNAs that regulate p53 activity. Rieko Ohki, Yosuke Ohsawa, Ryuichi Sakai. National Cancer Center Research Institute, Tokyo, Japan.
  • A neutralizing monoclonal antibody against FGFR1 inhibits growth of human renal cell carcinoma. Ilya Tsimafeyeu1, Hung Ta2, Alexey Kalachev1. 1Kidney Cancer Research Bureau, Moscow, Russian Federation, 2University of Toronto, Toronto, ON, Canada.
  • A novel role of FancJ in the cellular response to 5-FU-induced DNA damages. Hiroyuki Kitao1, Makoto Iimori1, Yoshihiko Fujinaka1, Nobuhide Kubo1, Ryota Nakanishi1, Munkhbold Tuul1, Keiji Yoshinaga1, Eriko Tokunaga1, Hiroshi Saeki1, Masaru Morita1, Yoshihiro Kakeji1, Minoru Takata2, Yoshihiko Maehara1. 1Kyushu University, Fukuoka, Japan, 2Kyoto University, Kyoto, Japan.
  • A novel thermally targeted therapeutic polypeptide for the treatment of glioblastoma. Joshua D. Hughes, Shadon Rollins, Gene L. Bidwell, III, Eddie Perkins, Drazen Raucher. University of Mississippi Medical Center, Jackson, MS.
  • A phase I/II trial of the histone deacetylase inhibitor vorinostat in combination with 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Peter M. Wilson, Anthony El-Khoueiry, Melissa J. LaBonte, Syma Iqbal, William Fazzone, Kathleen D. Danenberg, Dongyun Yang, Susan Groshen, Heinz-Josef Lenz, Robert D. Ladner. University of Southern California, Los Angeles, CA.
  • A single adenovirus expressing p53 protein and p21-targeting artificial microRNAs improves therapeutic outcome in cancer. Takashi Tokino, Masashi Idogawa, Yasushi Sasaki. Sapporo Medical University, Sapporo, Japan.
  • A small molecule inhibitor of phosphorylation-dependent protein-protein interaction. Nobumoto Watanabe, Hiroyuki Osada. RIKEN, ASI, Wako, Saitama, Japan.
  • Blockade of Wee1-dependent Hsp90 tyrosine phosphorylation sensitizes cancer cells to Hsp90 inhibition. Mehdi Mollapour1, Shinji Tsutsumi1, Kristin Beebe1, Dimitra Bourboulia1, Jane B. Trepel1, Chrisostomos Prodromou2, Laurence H. Pearl2, Len Neckers1. 1NCI, Bethesda, MD, 2ICR, London, United Kingdom.
  • CHAP31 is a novel useful HDAC inhibitor for treatment of esophageal cancer. Hisahiro Matsubara1, Kentaro Murakami1, Yasunori Akutsu1, Isamu Hoshino1, Norikazu Nishino2, Minoru Yoshida3. 1Chiba University, Graduate School of Medicine, Chiba, Japan, 2Kyushu Institute of Technology, Kitakyusyu, Japan, 3RIKEN, Wako, Japan.
  • Characterization of a new oncoantigen LESTA1 as a therapeutic target for lung and esophageal cancer. Minh-Hue Nguyen1, Yataro Daigo1, Junkichi Koinuma1, Koji Ueda2, Eiju Tsuchiya3, Yusuke Nakamura1. 1Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2Center for Genomic Medicine, RIKEN, Yokohama, Japan, 3Kanagawa Cancer Center Research Institute, Yokohama, Japan.
  • Characterization of a novel secreted oncoprotein LERP1 involved in lung and esophageal carcinogenesis. Daiki Miki1, Yataro Daigo1, Kazuaki Chayama2, Yusuke Nakamura1. 1Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2Hiroshima University, Hiroshima, Japan.
  • Chemical control of bone metastasis through the suppression of osteoclasts. Makoto Kawatani, Hiroyuki Osada. RIKEN, ASI, Wako-Shi, Saitama, Japan.
  • Chemical targeting of androgen receptor variants for inhibition of hormone-refractory prostate cancer cell growth. Sachiko Okabe, Tetsuo Mashima, Hiroyuki Seimiya. Division of Molecular Biotherapy, JFCR Cancer Chemotherapy Center, Tokyo, Japan.
  • CK2 kinase controls the tumor suppressor activity of the Ikaros transcription factor in human B cell lymphoma. Chunhua Song1, Zafer Gurel1, Kimberly J. Payne2, Sinisa Dovat1. 1University of Wisconsin, Madison, WI, 2Loma Linda University, Loma Linda, CA.
  • Correlation between efficacy of PI3K inhibitors and aberration of PIK3CA/PTEN in a panel of 39 human cancer cell lines (JFCR39). Shingo Dan1, Hironobu Sugita1, Mariko Seki1, Yumiko Mukai1, Kanami Yamazaki1, Yuichi Ishikawa2, Takao Yamori1. 1Cancer Chemotherapy Center of JFCR, Tokyo, Japan, 2Cancer Institute of JFCR, Tokyo, Japan.
  • Crude extracts of Caledonian red algae show anticancer activities. Veronique Guillemard, Claude Payri, Alain Videault. Research Institute for Development, Noumea, New Caledonia.
  • Design of novel biointerfaces using self-organization to control cancer cell behavior. Masaru Tanaka. Yamagata University, Yonezawa, Japan.
  • Development of a novel anti-HIF-1α mechanism-driven high-throughput screening system for rapidly selecting potent anticancer drugs. Yi Lu. University of Tennessee Health Science Center, Memphis, TN.
  • Essential role of TACC3 in the spindle assembly of ovarian cancer cells and its implication as the cancer therapeutic target. Ryoji Yao1, Yasuko Natsume1, Takao Yamori2, Tetsuo Noda1. 1The JFCR-Cancer Institute, Tokyo, Japan, 2The JFCR-Cancer Chemotherapy Center, Tokyo, Japan.
  • Ets-2 physically and functionally interacts with Prox1 in lymphatic endothelial cells. Yasuhiro Yoshimatsu, Hajime Mihira, Masato Morikawa, Tomoko Yamazaki, Caname Iwata, Yasuyuki Morishita, Tetsuro Watabe, Kohei Miyazono. University of Tokyo, Tokyo, Japan.
  • Evaluate the effects of tumor-associated macrophage on cancer progression in non-small cell lung cancer (NSCLC). Yu-Yuan Chen1, Huei-Wen Chen2, Chih-An Lin1, Chao-Chi Ho3, Pan-Chyr Yang2, Yuan Ang3. 1National Taiwan University, Taipei, Taiwan, 2National Taiwan University College of Medicine, Taipei, Taiwan, 3National Taiwan University Hospital, Taipei, Taiwan.
  • FGF-2 accelerates TGF-β-induced epithelial-mesenchymal transition and promotes invasion of cancer cells. Takuya Shirakihara1, Tatsuhiro Shibata1, Kohei Miyazono2, Masao Saitoh3. 1National Cancer Center Research Institute, Tokyo, Japan, 2the University of Tokyo, Tokyo, Japan, 3University of Yamanashi, Yamanashi, Japan.
  • Identification of a core cassette of 11 genes modulated by both vorinostat and LBH589 by microarray profiling in colon cancer cell lines, with xenograft validation. Melissa J. LaBonte, Peter M. Wilson, William Fazzone, Lisa W. Yan, Heinz-Josef Lenz, Anthony El-Khoueiry, Robert D. Ladner. University of Southern California, Los Angeles, CA.
  • Identification of a functional netrin-1 receptor that mediates anti-cell-death and cell motility of cancer cells and endothelial cells. Manabu Futamura, Noriaki Kitamura, Hirofumi Arakawa. National Cancer Center Research Institute, Tokyo, Japan.
  • Identification of a novel cancer-testis antigen LASTER as a prognostic biomarker and a therapeutic target for lung cancer. Masato Aragaki1, Yataro Daigo1, Takashi Fujitomo1, Eiju Tsuchiya2, Satoshi Kondo3, Yusuke Nakamura1. 1Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2Kanagawa Cancer Center Research Institute, Yokohama, Japan, 3Hokkaido University, Sapporo, Japan.
  • Identification of a novel oncogenic pathway initiated by LASHD as a diagnostic and therapeutic target. Ken Masuda1, Yataro Daigo1, Hideto Oshita1, Nobuoki Kohno2, Yusuke Nakamura1. 1Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2Hiroshima University, Hiroshima, Japan.
  • Identification of a novel therapeutic target oncoprotein LESOC1 involved in lung and esophageal carcinogenesis. Junkichi Koinuma1, Yataro Daigo1, Masao Hosokawa2, Eiju Tsuchiya3, Satoshi Kondo4, Yusuke Nakamura1. 1Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2Keiyukai Sapporo Hospital, Sapporo, Japan, 3Kanagawa Cancer Center Research Institute, Yokohama, Japan, 4Hokkaido University, Sapporo, Japan.
  • Infected carrier cells with replication-competent HSV-1 mutants enhance antitumor effect for ovarian cancer. Sawako Fujiwara, Akihiro Nawa, Fumi Goshima, Maki Kamakura, Fumitaka Kikkawa, Yukihiro Nishiyama. Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Inhibition of TGFβ pathway and EMT by a protein-bound polysaccharide, PSK . Yoshihiro Ono, Tetsu Hayashida, Ayano Konagai, Hirotoshi Hasegawa, Yoshiyuki Ishii, Takashi Endo, Koji Okabayashi, Shigeyuki Kawachi, Yuko Kitagawa. Keio University, Tokyo-To, Japan.
  • Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells. Noritaka Ohga1, Yasuhiro Hida2, Kunihiko Tsuchiya3, Chikara Muraki4, Kosuke Akiyama1, Miyako Kondoh1, Nako Maishi1, Takuro Kurosu1, Kohei Matsuda1, Yasunori Totsuka4, Masanobu Shindoh5, Kyoko Hida1. Departments of 1Vascular Biology, 4Oral and Maxillofacial Surgery, and 5Oral Pathological Science, Graduate School of Dental Medicine, University of Hokkaido, Sapporo, Hokkaido, Japan, Departments of 2Surgical Oncology and 3Renal and Genitourinary Surgery, Graduate School of Medicine, University of Hokkaido, Sapporo, Hokkaido, Japan.
  • Investigation of a novel potential therapeutic modality targeting to DEPDC1 for bladder cancer. Yosuke Harada1, Toyomasa Katagiri2, Mitsugu Kanehira3, Ryo Takata1, Tomoaki Fujioka3, Yusuke Nakamura1. 1Humane Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2Institute for Genome Research, University of Tokushima, Tokushima, Japan, 3Iwate Medical University, Iwate, Japan.
  • Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in breast cancer carcinogenesis though the regulation of Akt activity. Masahiko Ajiro1, Toyomasa Katagiri1, Koji Ueda2, Hidewaki Nakagawa2, Toshihiko Nishidate1, Chikako Fukukawa3, Yataro Daigo1, Yusuke Nakamura1. 1Humane Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2Biomarker Development, Center for Genomic Medicine, RIKEN, Tokyo, Japan, 3OncoTherapy Science, Inc., Tokyo, Japan.
  • JBIR-23, a novel compound of microbial origin, induces cytotoxicity against malignant mesothelioma cells by tubulin polymerization and apoptosis. Kazuo Shin-ya1, Motoki Takagi2, Ji-Hwan Hwang2, Hideki Murakami3, Yoshitaka Sekido3. 1National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan, 2Biomedicinal Information Research Center (BIRC), Japan Biological Informatics Consortium (JBIC), Tokyo, Japan, 3Aichi Cancer Center Research Institute, Aichi, Japan.
  • LMWH-taurocholate conjugate acts as a molecular targeting agent and inhibits tumor angiogenesis and tumor growth. Sungwoo Chung1, Sang Mun Bae2, Myungjin Lee3, Rang-Woon Park2, Seong Who Kim3, Seung-Ho Choi3, Sang Yoon Kim3, Youngro Byun1. 1Seoul National University College of Pharmacy, Seoul, Republic of Korea, 2Kyungpook National University School of Medicine, Daegu, Republic of Korea, 3University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Mechanism and targeting of kinase signaling downstream of CRLF2 in acute lymphoblastic leukemia. Akinori Yoda, Michal Bar-Natan, Martin Sattler, Jerome Ritz, David Frank, David Weinstock. Dana-Farber Cancer Institute, Boston, MA.
  • Methadone is a potent and mechanism-based inhibitor of metabolism by CYP19 (aromatase). Wenjie J. Lu, Zeruesenay Desta, David A. Flockhart. Indiana University, Indianapolis, IN.
  • Microenvironment-dependent function of ASC, a mediator protein for inflammasome and cell death, in carcinogenesis. Taniguchi Shun’ichiro, Kitazawa Masato, Itano Naoki, Takeoka Michiko. Shinshu University Graduate School of Medicine, Matsumoto, Nagano, Japan.
  • Molecular determinants of cancer cell susceptibility to HDMX inhibition. Federico Bernal1, Mark Wade2, Geoffrey M. Wahl2, Loren D. Walensky1. 1Dana-Farber Cancer Institute, Boston, MA, 2The Salk Institute for Biological Studies, La Jolla, CA.
  • Multidisciplinary treatments for gastric cancer with distant metastasis. Kiyonori Nishioka, Kenji Kobayashi, Keiko Tanizaki, Yuko Igarashi, Chihiro Yamanaka, Takamichi Komori, Takashi Matsumoto, Kou Takachi, Taro Aoki, Yoshio Uemura. Kinki Central Hospital, Itami City, Hyogo Prefecture, Japan.
  • Nectin-4 cell surface oncoprotein as a diagnostic and therapeutic target for lung cancer. Yataro Daigo1, Atsushi Takano1, Eiju Tsuchiya2, Yusuke Nakamura1. 1Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2Kanagawa Cancer Center Research Institute, Yokohama, Japan.
  • New synthetic small molecules inhibiting the spliceosome as antitumor drug leads. Thomas R. Webb, Philip Potter, Mahesh Gundluru, Chandraiah Lagisetti. St. Jude Children’s Research Hospital, Memphis, TN.
  • Novel spliceosome targeting agents modulate alternative splicing both in vitro and in vivo. Liying Fan, Chandraiah Lagisetti, Carol C. Edwards, Thomas R. Webb, Philip M. Potter. St. Jude Children’s Research Hospital, Memphis, TN.
  • Nuclear localization and Wnt signaling modulation by cellular FLIP-L. Ryohei Katayama1, Naoya Fujita1, Shinji Takada2, Ritsuko Takada2, Mikihiko Naito3. 1Japanese Foundation for Cancer Research, Tokyo, Japan, 2National Institutes of National Sciences, Okazaki, Aichi, Japan, 3National Institute of Health Science, Tokyo, Japan.
  • Oncoprotein Ski cooperates with histone deacetylase SIRT1 and facilitates suppression of p53 activity. Yasumichi Inoue, Aki Hanyu, Takeshi Imamura.Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Phase I clinical trial of novel HIG2-derived epitope peptide vaccine treatment for kidney cancer. Obara Wataru1, Takata Ryo1, Tsunoda Takuya2, Yoshida Koji2, Togashi Akira2, Nakamura Yusuke2, Fujioka Tomoaki1. 1Iwate Medical University, School of Medicine, Morioka, Japan, 2 Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Phase I clinical trial of novel HLA-A24 restricted CDCA1 peptide vaccine for prostate cancer. Obara Wataru1, Iwasaki Kazuhiro1, Tsunoda Takuya2, Yoshida Koji2, Nakamura Yusuke2, Fujioka Tomoaki1. 1Iwate Medical University, School of Medicine, Morioka, Japan, 2Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Phase I clinical trial of novel HLA-A24 restricted DEPDC1 and MPHOSPH1 peptide vaccine for bladder cancer. Obara Wataru1, Kanehira Mitsugu1, Takata Ryo1, Tsunoda Takuya2, Yoshida Koji2, Katagiri Toyomasa3, Nakamura Yusuke2, Fujioka Tomoaki1. 1Iwate Medical University, School of Medicine, Morioka, Japan, 2Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan, 3Tokushima University, Tokushima, Japan.
  • Pomegranate fruit extract exerts its antiproliferative, proapoptotic effect on prostate cancer cells through pathways independent of epigenetic modifications. Mitali Pandey, Catherine A. Wood, Emma S. Tomlinson Guns. The Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
  • PSF1 is a new therapeutic target for breast cancer. Izumi Nakahara1, Tatsuhiro Shibata2, Hiroshi Mizushima1, Hiroshi Tanaka1, Tsutomu Ohta2. 1Tokyo Medical and Dental University, Tokyo, Japan, 2National Cancer Center Research Institute, Tokyo, Japan.
  • Roles of TGF-β signals during endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells. Tetsuro Watabe, Takashi Kokudo, Hajime Mihira, Yuka Suzuki, Yasuhiro Yoshimatsu, Tomoko Yamazaki, Kohei Miyazono. University of Tokyo, Bunkyo-Ku, Tokyo, Japan.
  • Single-domain antibodies (nanobodies): A novel route for cancer therapeutics. Jan Gettemans, Anske Van den Abbeele, Sarah De Clercq, Ariane De Ganck, Joël Vandekerckhove. VIB and Ghent University, Ghent, Belgium.
  • Suppression of metastatic breast cancer by mitochondrial-targeted catalase. Jorming Goh, Christina Pettan-Brewer, John Morton, Linda Enns, Jesse Wiley, Warren Ladiges. University of Washington, Seattle, WA.
  • Sustained activation of ERK1/2 by inactivation of PP2A/B56 through immediate early gene response promotes carcinoma cell migration. Ei Kawahara, Eri Shimada, Yoshinari Yamamoto, Hiroshi Sakurai. Kanazawa University, Kanazawa, Japan.
  • Synergistic antitumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in A 549, H520, H157 lung cancer cell lines. Kim Kyu-Sik1, Oh In-Jae1, Kwon Yong-Soo1, Lim Sung-Chul1, Kim Young-Chul1, Song Sang-Yun2, Choi Song3, Choi Yoo-Duk3, Yun Mee-Sun3. 1Chonnam National University Hwasun Hospital Pulmonology, Hwasun, Jeollanamdo, Republic of Korea, 2Chonnam National University Hwasun Hospital, Chest Surgery, Lung and Esophageal Cancer Clinic, Hwasun, Jeollanamdo, Republic of Korea, 3Chonnam National University Hwasun Hospital Lung and Esophageal Cancer Clinic, Hwasun, Republic of Korea.
  • Targeted inhibition of regulatory T cells using a genomics-based strategy as a novel adjuvant for breast cancer immunotherapy. Michael M. Morse, Amy Hobeika, Delila Serra, Sharon Peplinski, Kim Lyerly, Timothy Clay, Gayathri R. Devi. Duke University, Durham, NC.
  • Targeting the AKT/mTOR pathway for BRCA1-deficient cancer therapy. Tao Xiang1, Yunhe Jia1, David Sherris2, Tej Pandita1, Qin Yang1. 1Washington University, St. Louis, MO, 2Paloma Pharmaceuticals, Jamaica Plain, MA.
  • Telomere fingerprinting for prediction of anticancer drug sensitivities. Yukiko Muramatsu1, Masaru Ueno2, Hidetoshi Tahara3, Takao Yamori4, Hiroyuki Seimiya1. 1Division of Molecular Biotherapy, JFCR Cancer Chemotherapy Center, Tokyo, Japan, 2Graduate School of Advanced Sciences of Matter, Hiroshima University, Hiroshima, Japan, 3Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan, 4Division of Molecular Pharmacology, JFCR Cancer Chemotherapy Center, Tokyo, Japan.
  • The combination of Akt inhibitors and chloroquine analogs can be an effective anticancer modality with low side effects. Hoyun Lee, Stacey Santi, V. Raja Solomon, Changkun Hu. Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario, Canada.
  • The relationship between circulating C-reactive protein, tissue angiogenic factor, hypoxia-inducible factor, and cancer-specific survival in patients with gastric cancer. Yasuhiko Mohri1, Chikao Miki1, Kouji Tanaka1, Donald C. McMillan2, Takeshi Yokoe1, Masaki Ohi1, Aya Kawamoto1, Masato Kusunoki1. 1Mie University Graduate School of Medicine, Tsu, Mie, Japan, 2University of Glasgow, Glasgow, United Kingdom.
  • Treatment with IGF-I receptor monoclonal antibody for gastrointestinal carcinomas. Y. Adachi, H. Oohashi, M. Ii, H. Li, H. Yamamoto, T. Endo, Y. Kato, D.P. Carbone, K. Imai, and Y. Shinomura. First Department of Internal Med, Sapporo Medical University, Sapporo, Japan, Sapporo Shirakabadai Hospital, Sapporo, Japan, and Vanderbilt University Medical Center, Nashville, TN.
  • Triggering receptor expressed on myeloid cells-1 (TREM-1) expression on macrophage in tumor progression. Wan-Yu Hsieh1, Yu-Yun Chen2, Yuan Ang2, Chao-Chi Ho2, Pan-Chyr Yang3, Huei-Wen Chen3. 1National Yang-Ming University, Taipei, 112, Taiwan, 2National Taiwan University Hospital, Taipei, Taiwan, 3National Taiwan University Medical College, Taipei, Taiwan.
Poster Session A Poster Session B Poster Session C Poster Session D